ClinicalTrials.gg
CompletedNCT01394016Updated Sep 19, 2024Results posted

A Phase 1 Study of LY2835219 In Participants With Advanced Cancer

A Phase 1 interventional study of Abemaciclib and Fulvestrant in Advanced Cancer, sponsored by Eli Lilly and Company. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 7 months after the study started (first participant enrolled Dec 2009, registered Jul 2011).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
225
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to determine a safe dose of Abemaciclib to be given to participants with advanced cancer and to determine any side effects that may be associated with Abemaciclib in this population. Efficacy measures will be used to assess the activity of Abemaciclib in this population.

02

Conditions studied

  • Advanced Cancer
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For all Parts (Dose escalation and expansion): The participant must be, in the judgment of the investigator, an appropriate candidate for experimental therapy either after available standard therapies have ceased to provide clinical benefit (Parts A, B, C, D, E and F) or in combination with fulvestrant (Part G only)
  • For Dose Escalation (Part A): The participant must have histological or cytological evidence of cancer, either a solid tumor or a lymphoma, which is advanced and/or
  • For Dose Expansion (Parts B, C, D, E, F and G): The participant must have histological or cytological evidence of one of the following cancers:

    • Part B: Non-small cell lung cancer of any subtype that is advanced and/or metastatic
    • Part C: Glioblastoma multiforme that has progressed or recurred after radiotherapy and/or chemotherapy
    • Part D: Breast cancer that is advanced and/or metastatic
    • Part E: Melanoma that is advanced and/or metastatic
    • Part F: Colorectal Cancer
    • Part G: Breast Cancer that is not only advanced and/or metastatic but also hormone receptor positive
  • As defined by the (RECIST 1.1) or the Revised Response Criteria for Malignant Lymphoma

    • For Parts A and G: Have measurable or nonmeasurable disease
    • For Parts B, C, D, E and F: Have
  • Have given written prior to any study-specific procedures
  • Have adequate hematologic, hepatic, and renal function
  • Have a performance status less than or equal to 1 for Dose Escalation (Part A) and less than or equal to 2 for Dose Confirmation (Parts B, C, D, E, F and G) on the (ECOG) scale
  • Have discontinued all previous therapies for cancer (including chemotherapy, radiotherapy, immunotherapy, and therapy) with the exception of fulvestrant (for Part G only) for at least 21 days for myelosuppressive agents or 14 days for nonmyelosuppressive agents prior to receiving study drug, and recovered from the acute effects of therapy (treatment related toxicity resolved to baseline) except for residual alopecia
  • Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures
  • Males and females with must agree to use medically approved precautions during the trial and for 3 months following the last dose of study drug
  • Females with child bearing potential must have a negative serum pregnancy test within 3 days of the first dose of study drug
  • Have an estimated of greater than or equal to 12 weeks
  • Are able to swallow capsules

Exclusion criteria

Exclusion Criteria:

  • Have received treatment with a drug that has not received regulatory approval for any indication within 14 or 21 days of the initial dose of study drug for a nonmyelosuppressive or myelosuppressive agent, respectively
  • Have a personal history of any of the following conditions: presyncope or syncope of either unexplained or cardiovascular etiology, ventricular arrhythmia (including but not limited to ventricular tachycardia and ventricular fibrillation), sudden cardiac death or sudden cardiac arrest
  • Have serious preexisting medical conditions that, in the judgment of the investigator, would preclude participation in this study (for example, history of major surgical resection involving the stomach or small bowel)
  • For Dose Escalation (Part A): Have central nervous system (CNS) or
  • For Dose Confirmation (Parts B, D, E, F and G): Have that is radiographically or clinically unstable less than 14 days prior to receiving study drug, regardless of whether they are receiving
  • For Dose Confirmation (Part C): Have glioblastoma multiforme that is radiographically or clinically unstable less than 14 days prior to receiving study drug, regardless of whether they are receiving corticosteroids
  • Have an acute leukemia
  • Have received an or allogeneic stem-cell transplant within 75 days of the initial dose of study drug
  • Females who are pregnant or lactating
  • Have active bacterial, fungal, and/or known viral infection (for example, [HIV] antibodies, surface antigen [HBSAg], or antibodies) Screening is not required for enrollment
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
225 participants (actual)

Study arms

  • Experimental
    Abemaciclib

    Participants received oral Abemaciclib administered on Days 1 through 28 of a 28-day cycle except in Cycle 1, where the study drug was administered as appropriate on Day -3 and then on Days 1 to 27. The treatment was continued until a discontinuation criterion was met or under Sponsor's discretion. Participants belonging to different Parts received the study drug as specified below: Part A: 50 mg/100 mg/150 mg/225 mg every 24 hours (Q24H) or 75mg/100 mg/150 mg/200 mg/275 mg every 12 hours (Q12H). Parts B, C, D, and E: 150 mg/200 mg Q12H. Part F: 150 mg Q12H. Part G: 200 mg Q12H along with 500 mg Fulvestrant administered intramuscularly.

    Drug: Abemaciclib · Drug: Fulvestrant

Interventions

  • Administered orally.

    Also known as: LY2835219

  • Fulvestrant is administered intramuscularly into the buttocks in Part G only.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Clinically Significant Effects

    The number of participants with clinically significant findings in the study were reported in this outcome measure.

    Time frame: Baseline up to 233 weeks

Secondary outcomes

  1. Percentage of Participants With Tumor Response - Overall Response Rate (ORR), Disease Control Rate (DCR)

    ORR is the percentage of participants who exhibit a confirmed complete response (CR) or partial response (PR) as classified by the investigator according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. DCR is defined as the percentage of participants in the analysis population who exhibit a stable disease (SD) or confirmed CR or PR relative to baseline during the study. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) for target lesions, no progression of non-target lesions, and no appearance of new lesions.

    Time frame: Baseline through Study Completion (Up to 285 weeks)

  2. Pharmacokinetics (PK): Maximum Observed Plasma Concentration at Steady State (Cmax,ss) of Abemaciclib

    PK: Cmax,ss of Abemaciclib.

    Time frame: Day 28 (0, 1, 2, 4, 6, 8, 10, 24 hours post-dose) of Cycle 1

  3. PK: Area Under the Steady State Plasma Concentration-time Curve Over 24 Hours (AUC 0-24hr,ss) of Abemaciclib

    PK: AUC 0-24hr,ss of Abemaciclib.

    Time frame: Day 28 (0, 1, 2, 4, 6, 8, 10, 24 hours post-dose) of Cycle 1

  4. Part A: Recommended Dose for Phase 2 Studies

    The recommended dose was determined based on a review of overall toxicity, dose reductions, omissions, and pharmacokinetic information from the study.

    Time frame: Baseline through Study Completion (Up to 285 weeks)

07

Results

Posted Sep 19, 2024

Participant flow

This study has Dose Escalation (Part A) and Dose Confirmation (Parts B, C, D, E, F, and G) phases. Participants included -Part A: participants with histological and cytological evidence of cancer; Part B: Non-small cell lung cancer; Part C: Glioblastoma multiforme; Part D: Advanced and/or metastatic breast cancer; Part E: Advanced and/or metastatic melanoma; Part F: Advanced and/or metastatic colorectal cancer. Part G: Advanced and/or metastatic breast cancer but also hormone receptor positive.

Participant flow — Overall Study
MilestonePart A - Cohort 1: 50 Milligrams (mg) Abemaciclib - Every 24 Hours (Q24H)Part A - Cohort 2: 100 mg Abemaciclib - Q24HPart A - Cohort 3: 150 mg Abemaciclib - Q24HPart A - Cohort 4: 225 mg Abemaciclib - Q24HPart A - Cohort 5: 75 mg Abemaciclib - Every 12 Hours (Q12H)Part A - Cohort 6: 100 mg Abemaciclib - Q12HPart A - Cohort 7: 150 mg Abemaciclib - Q12HPart A - Cohort 8: 200 mg Abemaciclib - Q12HPart A - Cohort 9: 275 mg Abemaciclib - Q12HPart B - 150 mg Abemaciclib - Q12HPart B - 200 mg Abemaciclib - Q12HPart C - 150 mg Abemaciclib - Q12HPart C - 200 mg Abemaciclib - Q12HPart D - 150 mg Abemaciclib - Q12HPart D - 200 mg Abemaciclib - Q12HPart E - 150 mg Abemaciclib - Q12HPart E - 200 mg Abemaciclib - Q12HPart F - 150 mg Abemaciclib - Q12HPart G - 200 mg Abemaciclib (Q12H) + Fulvestrant
Started4333343732642215252213131519
Received at least one dose of study drug4333343732642215252213131519
Completed2333343622438214222110111316
Not completed2000000112401313223
Withdrew: Progressive disease2000000000000000000
Withdrew: Withdrawal by subject0000000111400313112
Withdrew: Adverse event0000000001000000110
Withdrew: Sponsor decision0000000000001000000
Withdrew: Lost to follow-up0000000000000000001

Outcome measures

PrimaryNumber of Participants With Clinically Significant Effects

The number of participants with clinically significant findings in the study were reported in this outcome measure.

Time frame:
Baseline up to 233 weeks
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Effects
ParticipantsPart A - Cohort 1: 50 mg Abemaciclib - Q24HPart A - Cohort 2: 100 mg Abemaciclib - Q24HPart A - Cohort 3: 150 mg Abemaciclib - Q24HPart A - Cohort 4: 225 mg Abemaciclib - Q24HPart A - Cohort 5: 75 mg Abemaciclib - Q12HPart A - Cohort 6: 100 mg Abemaciclib - Q12HPart A - Cohort 7: 150 mg Abemaciclib - Q12HPart A - Cohort 8: 200 mg Abemaciclib - Q12HPart A - Cohort 9: 275 mg Abemaciclib - Q12HPart B - 150 mg Abemaciclib - Q12HPart B - 200 mg Abemaciclib - Q12HPart C - 150 mg Abemaciclib - Q12HPart C - 200 mg Abemaciclib - Q12HPart D - 150 mg Abemaciclib - Q12HPart D - 200 mg Abemaciclib - Q12HPart E - 150 mg Abemaciclib - Q12HPart E - 200 mg Abemaciclib - Q12HPart F - 150 mg Abemaciclib - Q12HPart G - 200 mg Abemaciclib (Q12H) + Fulvestrant
Number of Participants With Clinically Significant Effects0000000121501240206
SecondaryPercentage of Participants With Tumor Response - Overall Response Rate (ORR), Disease Control Rate (DCR)

ORR is the percentage of participants who exhibit a confirmed complete response (CR) or partial response (PR) as classified by the investigator according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. DCR is defined as the percentage of participants in the analysis population who exhibit a stable disease (SD) or confirmed CR or PR relative to baseline during the study. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) for target lesions, no progression of non-target lesions, and no appearance of new lesions.

Time frame:
Baseline through Study Completion (Up to 285 weeks)
Reported as:
Number · Percentage of participants
Percentage of Participants With Tumor Response - Overall Response Rate (ORR), Disease Control Rate (DCR)
Percentage of participantsPart B - 150 mg Abemaciclib - Q12HPart B - 200 mg Abemaciclib - Q12HPart C - 150 mg Abemaciclib - Q12HPart C - 200 mg Abemaciclib - Q12HPart D - 150 mg Abemaciclib - Q12HPart D - 200 mg Abemaciclib - Q12HPart E - 150 mg Abemaciclib - Q12HPart E - 200 mg Abemaciclib - Q12HPart F - 150 mg Abemaciclib - Q12HPart G - 200 mg Abemaciclib (Q12H) + Fulvestrant (Measurable Disease)Part G - 200 mg Abemaciclib (Q12H) + Fulvestrant (Non-measurable Disease)
ORR3.8 (0.1 to 19.6)2.4 (0.1 to 12.6)0 (NA to NA)0 (NA to NA)32.0 (14.9 to 53.5)18.2 (5.2 to 40.3)0 (NA to NA)7.7 (0.2 to 36.0)0 (NA to NA)45.5 (16.7 to 76.6)0 (NA to NA)
DCR42.3 (23.4 to 63.1)52.4 (36.4 to 68.0)0 (NA to NA)20 (4.3 to 48.1)68.0 (46.5 to 85.1)72.7 (49.8 to 89.3)23.1 (5.0 to 53.8)30.8 (9.1 to 61.4)13.3 (1.7 to 40.5)72.7 (39.0 to 94.0)87.5 (47.3 to 99.7)
SecondaryPharmacokinetics (PK): Maximum Observed Plasma Concentration at Steady State (Cmax,ss) of Abemaciclib

PK: Cmax,ss of Abemaciclib.

Time frame:
Day 28 (0, 1, 2, 4, 6, 8, 10, 24 hours post-dose) of Cycle 1
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Pharmacokinetics (PK): Maximum Observed Plasma Concentration at Steady State (Cmax,ss) of Abemaciclib
nanograms per milliliter (ng/mL)50 mg Abemaciclib - Q24H100 mg Abemaciclib - Q24H150 mg Abemaciclib - Q24H225 mg Abemaciclib - Q24H75 mg Abemaciclib - Q12H100 mg Abemaciclib - Q12H150 mg Abemaciclib - Q12H200 mg Abemaciclib - Q12H275 mg Abemaciclib - Q12H
Pharmacokinetics (PK): Maximum Observed Plasma Concentration at Steady State (Cmax,ss) of AbemaciclibNA ± NA102 ± 198189 ± 35121 ± 3858.7 ± 37226 ± 51249 ± 86298 ± 72—
SecondaryPK: Area Under the Steady State Plasma Concentration-time Curve Over 24 Hours (AUC 0-24hr,ss) of Abemaciclib

PK: AUC 0-24hr,ss of Abemaciclib.

Time frame:
Day 28 (0, 1, 2, 4, 6, 8, 10, 24 hours post-dose) of Cycle 1
Reported as:
Geometric mean · nanogram hour per milliliter (ng*h/mL)
PK: Area Under the Steady State Plasma Concentration-time Curve Over 24 Hours (AUC 0-24hr,ss) of Abemaciclib
nanogram hour per milliliter (ng*h/mL)50 mg Abemaciclib - Q24H100 mg Abemaciclib - Q24H150 mg Abemaciclib - Q24H225 mg Abemaciclib - Q24H75 mg Abemaciclib - Q12H100 mg Abemaciclib - Q12H150 mg Abemaciclib - Q12H200 mg Abemaciclib - Q12H275 mg Abemaciclib - Q12H
PK: Area Under the Steady State Plasma Concentration-time Curve Over 24 Hours (AUC 0-24hr,ss) of AbemaciclibNA ± NA1840 ± 172NA ± NANA ± NA1300 ± 493910 ± 534280 ± 945520 ± 70—
SecondaryPart A: Recommended Dose for Phase 2 Studies

The recommended dose was determined based on a review of overall toxicity, dose reductions, omissions, and pharmacokinetic information from the study.

Time frame:
Baseline through Study Completion (Up to 285 weeks)
Reported as:
Number · milligrams every 12 hours (mg Q12H)
Part A: Recommended Dose for Phase 2 Studies
milligrams every 12 hours (mg Q12H)Part A - Abemaciclib
Part A: Recommended Dose for Phase 2 Studies200

Adverse events

Collected over Baseline through End of Treatment (Up to 645 weeks). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A - Cohort 1: 50 mg Abemaciclib - Q24H0/4 (0%)0/4 (0%)4/4 (100%)
Part A - Cohort 2: 100 mg Abemaciclib - Q24H0/3 (0%)1/3 (33.3%)3/3 (100%)
Part A - Cohort 3: 150 mg Abemaciclib - Q24H0/3 (0%)1/3 (33.3%)3/3 (100%)
Part A - Cohort 4: 225 mg Abemaciclib - Q24H0/3 (0%)0/3 (0%)3/3 (100%)
Part A - Cohort 5: 75 mg Abemaciclib - Q12H0/3 (0%)1/3 (33.3%)3/3 (100%)
Part A - Cohort 6: 100 mg Abemaciclib - Q12H0/4 (0%)1/4 (25%)4/4 (100%)
Part A - Cohort 7: 150 mg Abemaciclib - Q12H0/3 (0%)1/3 (33.3%)3/3 (100%)
Part A - Cohort 8: 200 mg Abemaciclib - Q12H0/7 (0%)1/7 (14.3%)7/7 (100%)
Part A - Cohort 9: 275 mg Abemaciclib - Q12H1/3 (33.3%)1/3 (33.3%)3/3 (100%)
Part B - 150 mg Abemaciclib - Q12H3/26 (11.5%)7/26 (26.9%)26/26 (100%)
Part B - 200 mg Abemaciclib - Q12H15/42 (35.7%)15/42 (35.7%)42/42 (100%)
Part C - 150 mg Abemaciclib - Q12H0/2 (0%)1/2 (50%)2/2 (100%)
Part C - 200 mg Abemaciclib - Q12H7/15 (46.7%)3/15 (20%)15/15 (100%)
Part D - 150 mg Abemaciclib - Q12H4/25 (16%)5/25 (20%)25/25 (100%)
Part D - 200 mg Abemaciclib - Q12H0/22 (0%)7/22 (31.8%)22/22 (100%)
Part E - 150 mg Abemaciclib - Q12H1/13 (7.7%)5/13 (38.5%)13/13 (100%)
Part E - 200 mg Abemaciclib - Q12H5/13 (38.5%)5/13 (38.5%)13/13 (100%)
Part F - 150 mg Abemaciclib - Q12H0/15 (0%)3/15 (20%)15/15 (100%)
Part G - 200 mg Abemaciclib (Q12H) + Fulvestrant2/19 (10.5%)4/19 (21.1%)19/19 (100%)
Most frequent serious events
Showing 10 of 70
Most frequent serious events
EventPart A - Cohort 1: 50 mg Abemaciclib - Q24HPart A - Cohort 2: 100 mg Abemaciclib - Q24HPart A - Cohort 3: 150 mg Abemaciclib - Q24HPart A - Cohort 4: 225 mg Abemaciclib - Q24HPart A - Cohort 5: 75 mg Abemaciclib - Q12HPart A - Cohort 6: 100 mg Abemaciclib - Q12HPart A - Cohort 7: 150 mg Abemaciclib - Q12HPart A - Cohort 8: 200 mg Abemaciclib - Q12HPart A - Cohort 9: 275 mg Abemaciclib - Q12HPart B - 150 mg Abemaciclib - Q12HPart B - 200 mg Abemaciclib - Q12HPart C - 150 mg Abemaciclib - Q12HPart C - 200 mg Abemaciclib - Q12HPart D - 150 mg Abemaciclib - Q12HPart D - 200 mg Abemaciclib - Q12HPart E - 150 mg Abemaciclib - Q12HPart E - 200 mg Abemaciclib - Q12HPart F - 150 mg Abemaciclib - Q12HPart G - 200 mg Abemaciclib (Q12H) + Fulvestrant
SeizureNervous system disorders0/40/30/30/30/30/40/30/70/30/260/421/21/150/250/220/130/130/150/19
Small intestinal obstructionGastrointestinal disorders0/40/30/30/31/31/40/30/70/30/260/420/20/150/250/220/130/130/150/19
ChillsGeneral disorders0/40/31/30/30/30/40/30/70/30/260/420/20/150/250/220/130/130/150/19
BronchitisInfections and infestations0/40/31/30/30/30/40/30/70/30/260/420/20/150/250/220/130/130/150/19
Large intestine infectionInfections and infestations0/40/31/30/30/30/40/30/70/30/260/420/20/150/250/220/130/130/150/19
Neutropenic sepsisInfections and infestations0/40/30/30/30/30/40/30/71/30/260/420/20/150/250/220/130/130/150/19
PneumoniaInfections and infestations0/40/31/30/30/30/41/30/70/32/262/420/20/150/252/220/131/130/150/19
Tumour painNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/41/30/30/30/30/40/30/70/30/260/420/20/150/250/220/130/130/150/19
Pneumatosis intestinalisGastrointestinal disorders0/40/30/30/30/31/40/30/70/30/260/420/20/150/250/220/130/130/150/19
Abdominal wall abscessInfections and infestations0/40/30/30/30/30/40/31/70/30/260/420/20/150/250/220/130/130/150/19
Most frequent other events
Showing 10 of 521
Most frequent other events
EventPart A - Cohort 1: 50 mg Abemaciclib - Q24HPart A - Cohort 2: 100 mg Abemaciclib - Q24HPart A - Cohort 3: 150 mg Abemaciclib - Q24HPart A - Cohort 4: 225 mg Abemaciclib - Q24HPart A - Cohort 5: 75 mg Abemaciclib - Q12HPart A - Cohort 6: 100 mg Abemaciclib - Q12HPart A - Cohort 7: 150 mg Abemaciclib - Q12HPart A - Cohort 8: 200 mg Abemaciclib - Q12HPart A - Cohort 9: 275 mg Abemaciclib - Q12HPart B - 150 mg Abemaciclib - Q12HPart B - 200 mg Abemaciclib - Q12HPart C - 150 mg Abemaciclib - Q12HPart C - 200 mg Abemaciclib - Q12HPart D - 150 mg Abemaciclib - Q12HPart D - 200 mg Abemaciclib - Q12HPart E - 150 mg Abemaciclib - Q12HPart E - 200 mg Abemaciclib - Q12HPart F - 150 mg Abemaciclib - Q12HPart G - 200 mg Abemaciclib (Q12H) + Fulvestrant
ConstipationGastrointestinal disorders2/43/31/33/32/32/41/32/72/315/2626/421/24/157/2510/225/132/136/155/19
DiarrhoeaGastrointestinal disorders2/41/32/31/32/34/42/37/73/316/2629/421/29/1521/2518/229/1313/1310/1517/19
NauseaGastrointestinal disorders2/42/32/33/32/32/42/36/73/318/2631/420/26/1519/2518/2213/135/1310/1518/19
FatigueGeneral disorders3/43/33/33/31/34/43/35/72/320/2637/420/214/1520/2517/2211/139/1310/1515/19
ProstatitisReproductive system and breast disorders0/30/10/10/20/10/2—1/1—0/110/210/10/60/1—0/100/80/6—
Vulvovaginal drynessReproductive system and breast disorders0/10/20/21/10/20/20/30/60/30/150/210/10/90/240/220/30/50/90/19
HypertensionVascular disorders0/42/33/33/31/32/42/34/70/315/2623/421/26/158/2510/224/1310/136/156/19
Drug hypersensitivityImmune system disorders0/41/30/31/30/33/40/31/71/37/266/420/23/157/2510/221/131/133/159/19
Peripheral sensory neuropathyNervous system disorders3/42/32/31/32/33/41/32/70/37/2611/420/22/159/2510/224/134/137/153/19
AnaemiaBlood and lymphatic system disorders0/41/31/32/30/31/41/31/72/313/2625/420/23/155/2511/226/135/136/157/19

Baseline characteristics

All participants who received at least one dose of study drug.

Age, Categorical
Age, Categorical(Participants)Part A - Cohort 1: 50 mg Abemaciclib - Q24HPart A - Cohort 2: 100 mg Abemaciclib - Q24HPart A - Cohort 3: 150 mg Abemaciclib - Q24HPart A - Cohort 4: 225 mg Abemaciclib - Q24HPart A - Cohort 5: 75 mg Abemaciclib - Q12HPart A - Cohort 6: 100 mg Abemaciclib - Q12HPart A - Cohort 7: 150 mg Abemaciclib - Q12HPart A - Cohort 8: 200 mg Abemaciclib- Q12HPart A - Cohort 9: 275 mg Abemaciclib - Q12HPart B - 150 mg Abemaciclib - Q12HPart B - 200 mg Abemaciclib - Q12HPart C - 150 mg Abemaciclib - Q12HPart C - 200 mg Abemaciclib - Q12HPart D - 150 mg Abemaciclib - Q12HPart D - 200 mg Abemaciclib - Q12HPart E - 150 mg Abemaciclib - Q12HPart E - 200 mg Abemaciclib - Q12HPart F - 150 mg Abemaciclib - Q12HPart G - 200 mg Abemaciclib (Q12H)+ FulvestrantTotal
<=18 years00000000000000000000
Between 18 and 65 years4111242521123013181955812136
>=65 years02221012115192273887789
Sex: Female, Male
Sex: Female, Male(Participants)Part A - Cohort 1: 50 mg Abemaciclib - Q24HPart A - Cohort 2: 100 mg Abemaciclib - Q24HPart A - Cohort 3: 150 mg Abemaciclib - Q24HPart A - Cohort 4: 225 mg Abemaciclib - Q24HPart A - Cohort 5: 75 mg Abemaciclib - Q12HPart A - Cohort 6: 100 mg Abemaciclib - Q12HPart A - Cohort 7: 150 mg Abemaciclib - Q12HPart A - Cohort 8: 200 mg Abemaciclib- Q12HPart A - Cohort 9: 275 mg Abemaciclib - Q12HPart B - 150 mg Abemaciclib - Q12HPart B - 200 mg Abemaciclib - Q12HPart C - 150 mg Abemaciclib - Q12HPart C - 200 mg Abemaciclib - Q12HPart D - 150 mg Abemaciclib - Q12HPart D - 200 mg Abemaciclib - Q12HPart E - 150 mg Abemaciclib - Q12HPart E - 200 mg Abemaciclib - Q12HPart F - 150 mg Abemaciclib - Q12HPart G - 200 mg Abemaciclib (Q12H)+ FulvestrantTotal
Female122122363152119242235919150
Male311212010112116101086075
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A - Cohort 1: 50 mg Abemaciclib - Q24HPart A - Cohort 2: 100 mg Abemaciclib - Q24HPart A - Cohort 3: 150 mg Abemaciclib - Q24HPart A - Cohort 4: 225 mg Abemaciclib - Q24HPart A - Cohort 5: 75 mg Abemaciclib - Q12HPart A - Cohort 6: 100 mg Abemaciclib - Q12HPart A - Cohort 7: 150 mg Abemaciclib - Q12HPart A - Cohort 8: 200 mg Abemaciclib- Q12HPart A - Cohort 9: 275 mg Abemaciclib - Q12HPart B - 150 mg Abemaciclib - Q12HPart B - 200 mg Abemaciclib - Q12HPart C - 150 mg Abemaciclib - Q12HPart C - 200 mg Abemaciclib - Q12HPart D - 150 mg Abemaciclib - Q12HPart D - 200 mg Abemaciclib - Q12HPart E - 150 mg Abemaciclib - Q12HPart E - 200 mg Abemaciclib - Q12HPart F - 150 mg Abemaciclib - Q12HPart G - 200 mg Abemaciclib (Q12H)+ FulvestrantTotal
Hispanic or Latino010011101230044213327
Not Hispanic or Latino4233232722439215211811121116197
Unknown or Not Reported00000000000000000101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A - Cohort 1: 50 mg Abemaciclib - Q24HPart A - Cohort 2: 100 mg Abemaciclib - Q24HPart A - Cohort 3: 150 mg Abemaciclib - Q24HPart A - Cohort 4: 225 mg Abemaciclib - Q24HPart A - Cohort 5: 75 mg Abemaciclib - Q12HPart A - Cohort 6: 100 mg Abemaciclib - Q12HPart A - Cohort 7: 150 mg Abemaciclib - Q12HPart A - Cohort 8: 200 mg Abemaciclib- Q12HPart A - Cohort 9: 275 mg Abemaciclib - Q12HPart B - 150 mg Abemaciclib - Q12HPart B - 200 mg Abemaciclib - Q12HPart C - 150 mg Abemaciclib - Q12HPart C - 200 mg Abemaciclib - Q12HPart D - 150 mg Abemaciclib - Q12HPart D - 200 mg Abemaciclib - Q12HPart E - 150 mg Abemaciclib - Q12HPart E - 200 mg Abemaciclib - Q12HPart F - 150 mg Abemaciclib - Q12HPart G - 200 mg Abemaciclib (Q12H)+ FulvestrantTotal
American Indian or Alaska Native00000000000000000000
Asian00000000113000100118
Native Hawaiian or Other Pacific Islander00000000000000000000
Black or African American00000000010001100205
White4333343722439215242013131218212
More than one race00000000000000000000
Unknown or Not Reported00000000000000000000
Region of Enrollment
Region of Enrollment(Participants)Part A - Cohort 1: 50 mg Abemaciclib - Q24HPart A - Cohort 2: 100 mg Abemaciclib - Q24HPart A - Cohort 3: 150 mg Abemaciclib - Q24HPart A - Cohort 4: 225 mg Abemaciclib - Q24HPart A - Cohort 5: 75 mg Abemaciclib - Q12HPart A - Cohort 6: 100 mg Abemaciclib - Q12HPart A - Cohort 7: 150 mg Abemaciclib - Q12HPart A - Cohort 8: 200 mg Abemaciclib- Q12HPart A - Cohort 9: 275 mg Abemaciclib - Q12HPart B - 150 mg Abemaciclib - Q12HPart B - 200 mg Abemaciclib - Q12HPart C - 150 mg Abemaciclib - Q12HPart C - 200 mg Abemaciclib - Q12HPart D - 150 mg Abemaciclib - Q12HPart D - 200 mg Abemaciclib - Q12HPart E - 150 mg Abemaciclib - Q12HPart E - 200 mg Abemaciclib - Q12HPart F - 150 mg Abemaciclib - Q12HPart G - 200 mg Abemaciclib (Q12H)+ FulvestrantTotal
United States4333343732642215252213131519225
08

Study locations

3 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Santa Monica, California 90404, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Boston, Massachusetts 02115, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    San Antonio, Texas 78229, United States
09

References and documents

Publications

  • Tate SC, Sykes AK, Kulanthaivel P, Chan EM, Turner PK, Cronier DM. A Population Pharmacokinetic and Pharmacodynamic Analysis of Abemaciclib in a Phase I Clinical Trial in Cancer Patients. Clin Pharmacokinet. 2018 Mar;57(3):335-344. doi: 10.1007/s40262-017-0559-8. PubMed 28540640 ↗
  • Gelbert LM, Cai S, Lin X, Sanchez-Martinez C, Del Prado M, Lallena MJ, Torres R, Ajamie RT, Wishart GN, Flack RS, Neubauer BL, Young J, Chan EM, Iversen P, Cronier D, Kreklau E, de Dios A. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Invest New Drugs. 2014 Oct;32(5):825-37. doi: 10.1007/s10637-014-0120-7. Epub 2014 Jun 13. PubMed 24919854 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2009 to primary completion in May 2014, 53 months.

Results were first posted in Sep 2024, 10 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2011
First posted
Jul 14, 2011
StartActual
Dec 7, 2009
Primary completionActual
May 29, 2014
CompletionActual
Apr 12, 2022
Results first posted
Sep 19, 2024
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01394016
Responsible party
Sponsor
First posted
Jul 14, 2011
Start date
Dec 7, 2009
Primary completion
May 29, 2014
Completion
Apr 12, 2022
Results posted
Sep 19, 2024
Last update
Sep 19, 2024

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abemaciclib

Start the discussion